GHK-Cu
Also known as Copper peptide, Copper tripeptide-1
A reasonable skincare ingredient with thin but real human data. Injecting it is a different product with almost no safety evidence.
Information only. Not medical advice. Talk to a doctor before you start, stop or change anything.
This profile covers two very different products. Creams and serums are cosmetics. Injectable versions are unapproved drugs.
What people claim
- Firms skin and smooths wrinkles
- Speeds wound healing
- Regrows hair
- Injected, it rejuvenates the whole body
What the evidence shows
- Reviews describe 12-week facial cream studies in about 70 women with better fine lines and skin density. These are small cosmetic studies, not large independent trials.[1]
- A randomized trial after CO2 laser resurfacing found no objective improvement in wrinkles or skin quality, although patients were more satisfied.[2]
- We found no solid human trial showing hair regrowth. That claim rests mainly on lab research.[1]
- For injected GHK-Cu, FDA describes human data as limited.[3]
Known risks
Reported side effects
Moderated user reports are not open yet, so nothing is shown here. They will be labelled as unverified personal accounts.
Legal status
A summary, not legal advice. Rules change, and sport bans are separate.
Cosmetic, injectable unapproved
Fine as a cosmetic ingredient. Injectable GHK-Cu is unapproved and is not one of the six peptides in the Oct 2026 HHS policy.
Cosmetic, injectable unlicensed
Fine as a cosmetic ingredient. No licensed injectable medicine.
Cosmetic, injectable unapproved
Skincare is sold normally. TGA names injectable GHK-Cu among unapproved peptide products it has not evaluated.
Cosmetic, injectable not authorised
Listed as a cosmetic ingredient. No authorised injectable medicine.
Sources
- 1.GHK peptide as a natural modulator of multiple cellular pathways in skin regenerationBioMed Research International, 2015
- 2.Effects of topical copper tripeptide complex on CO2 laser-resurfaced skinArchives of Facial Plastic Surgery, 2006
- 3.Bulk drug substances that may present significant safety risksUS FDA
- 4.Importing, compounding and supplying unapproved peptide productsTGA Australia
Profile last checked 7 Nov 2026.